Zilretta (triamcinolone acetonide extended-release intraarticular injection) — Medica
Osteoarthritis pain of the knee
Preferred products
- immediate-release triamcinolone acetonide
- betamethasone sodium phosphate/betamethasone acetate
- dexamethasone sodium phosphate
- methylprednisolone acetate
Initial criteria
- Diagnosis of the knee to be treated is confirmed by radiologic evidence of knee osteoarthritis (e.g., x-ray, magnetic resonance imaging, computed tomography scan, or ultrasound).
- Patient has tried at least ONE intraarticular corticosteroid injection in the knee to be treated [documentation required] (e.g., immediate-release triamcinolone acetonide, betamethasone sodium phosphate/betamethasone acetate, dexamethasone sodium phosphate, or methylprednisolone acetate).
- Patient is not receiving re-treatment of knee(s) previously treated with Zilretta.
Approval duration
30 days (one injection per treated knee)